Tvardi Therapeutics, Inc. (TVRD) SEC Filings — 2025
21 SEC filings for Tvardi Therapeutics, Inc. (TVRD) in 2025.
Filings
- Tvardi Therapeutics Appoints New Directors and CMO — 8-K · Dec 18, 2025
- Tvardi Therapeutics Files 8-K — 8-K · Nov 19, 2025
- Tvardi's Cash Infusion Post-Merger Masks Deepening Burn Rate — 10-Q · Nov 13, 2025
- Tvardi Faces Going Concern Doubt After Merger, IPF Trial Misses Goals — S-1/A · Oct 20, 2025
- Tvardi Therapeutics Files 8-K — 8-K · Oct 14, 2025
- Tvardi Therapeutics Files S-1/A for Resale, Eyes Key Clinical Readouts — S-1/A · Oct 7, 2025
- Tvardi Therapeutics Files 8-K on Financials — 8-K · Aug 14, 2025
- Tvardi Swings to Q2 Profit on Merger Boost, Cash Dips — 10-Q · Aug 14, 2025
- Tvardi Therapeutics Appoints New CEO, Dr. Jonathan Lim — 8-K · Jul 14, 2025
- Tvardi Therapeutics, Inc. 8-K Filing — 8-K · Jun 9, 2025
- Tvardi Therapeutics, Inc. S-1 Filing — S-1 · May 30, 2025
- Tvardi Therapeutics Files 8-K — 8-K · May 27, 2025
- Tvardi Therapeutics Files 8-K/A Amendment — 8-K/A · May 13, 2025
- Tvardi Therapeutics Files Q1 2025 10-Q — 10-Q · May 13, 2025
- Tvardi Therapeutics Reports Material Definitive Agreement & Acquisition — 8-K · Apr 15, 2025
- Cara Therapeutics, Inc. 8-K Filing — 8-K · Apr 11, 2025
- Cara Therapeutics Files 8-K — 8-K · Apr 1, 2025
- Cara Therapeutics to be Acquired by PolyPid Ltd. — 8-K · Mar 24, 2025
- Cara Therapeutics Files 2024 10-K — 10-K · Mar 11, 2025
- PolyPid to Acquire Cara Therapeutics for $93.3M — 8-K · Jan 21, 2025
- Viatris to Acquire Cara Therapeutics for $3.00/share + CVR — 8-K · Jan 17, 2025